Compare GNTX & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNTX | LIVN |
|---|---|---|
| Founded | 1974 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 1995 | 2015 |
| Metric | GNTX | LIVN |
|---|---|---|
| Price | $19.92 | $78.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $25.28 | ★ $90.55 |
| AVG Volume (30 Days) | ★ 3.0M | 517.2K |
| Earning Date | 10-23-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.00 | ★ 2.33 |
| Revenue | ★ $2,534,268,965.00 | N/A |
| Revenue This Year | $3.94 | $9.65 |
| Revenue Next Year | $6.28 | $7.10 |
| P/E Ratio | ★ $20.16 | $35.01 |
| Revenue Growth | ★ 9.55 | N/A |
| 52 Week Low | $19.75 | $48.82 |
| 52 Week High | $26.48 | $85.76 |
| Indicator | GNTX | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 50.35 |
| Support Level | N/A | $74.69 |
| Resistance Level | $22.25 | $82.39 |
| Average True Range (ATR) | 0.52 | 2.20 |
| MACD | -0.05 | 0.26 |
| Stochastic Oscillator | 8.59 | 48.00 |
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue was about 89% of total revenue in 2025, down from 98% in 2024 due to the Voxx acquisition in April 2025. The company is constantly developing new applications for the technology to remain on top. Sales in 2025 totaled about $2.5 billion with 44.8 million mirrors shipped. The unit mix breaks out as 64% interior and 36% exterior versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.